Akari Therapeutics (AKTX)
NASDAQ: AKTX
· Real-Time Price · USD
1.10
-0.01 (-0.90%)
At close: Sep 25, 2025, 3:59 PM
1.07
-2.73%
After-hours: Sep 25, 2025, 05:14 PM EDT
-0.90% (1D)
| Bid | 1.1 |
| Market Cap | 17.94K |
| Revenue (ttm) | 26K |
| Net Income (ttm) | -12.27M |
| EPS (ttm) | -2.58 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | -1.65 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.15 |
| Volume | 500,048 |
| Avg. Volume (20D) | 166,026 |
| Open | 1.10 |
| Previous Close | 1.11 |
| Day's Range | 1.04 - 1.24 |
| 52-Week Range | 0.57 - 3.85 |
| Beta | 0.27 |
| Ex-Dividend Date | n/a |
About AKTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AKTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AKTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+5.11%
AKTX stock has given up its prior loss. Akari Ther...
Unlock content with
Pro Subscription
1 week ago
+5.11%
Akari Therapeutics shares are trading lower. The company announced that it has filed a provisional patent application with the United States Patent and Trademark Office covering the its antibody drug conjugate platform using its spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells.
